Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMINA IgAN: zigakibart + atrasentan versus zigakibart + placebo in primary IgA nephropathy
MOH_2026-08-25_017005Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Aug 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing zigakibart + atrasentan with zigakibart + placebo (2 arms). Primary endpoints: Reduction in proteinuria and Delay of disease progression. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
zigakibartatrasentan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on MOH_2026-08-25_017005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-25_017005.